聚焦2026年Biomedtracker数据监测医疗保健预ASCO报告(英)。Clinical Impact Puxi-Sam’s ORR is among the highest reported in thissetting in endometrial cancer In BLUESTAR, Puxi-Sam met expectations for benefits in relapsed endometrial cancer with a confirmed ORR of 48.0%, DCR of 86% at 12 weeks and median PFS of 8.1 months at the highest dose level.
聚焦2026年Biomedtracker数据监测医疗保健预ASCO报告(英)。Clinical Impact Puxi-Sam’s ORR is among the highest reported in thissetting in endometrial cancer In BLUESTAR, Puxi-Sam met expectations for benefits in relapsed endometrial cancer with a confirmed ORR of 48.0%, DCR of 86% at 12 weeks and median PFS of 8.1 months at the highest dose level.
聚焦2026年Biomedtracker数据监测医疗保健预ASCO报告(英)。Clinical Impact Puxi-Sam’s ORR is among the highest reported in thissetting in endometrial cancer In BLUESTAR, Puxi-Sam met expectations for benefits in relapsed endometrial cancer with a confirmed ORR of 48.0%, DCR of 86% at 12 weeks and median PFS of 8.1 months at the highest dose level.
覆盖 2026 年,全文共 135 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
重点分析了医疗等议题。